Boston & New England CRE News In Your Inbox.
Sign up for Connect emails to stay informed with CRE stories that are 150 words or less.
McCord Acquires 65K-SF Life Science Facility in Boston
Houston and Boston-based opportunistic real estate company McCord has acquired 30 Bearfoot, a 64,736-square-foot biomanufacturing and research and development facility in Boston’s MetroWest Life Sciences Cluster. The sales price was not disclosed.
McCord is implementing extensive renovations to 30 Bearfoot to provide a modern aesthetic and environment fit for mission critical life science companies. The facility is formerly home to GlaxoSmithKline (GSK). Boston’s MetroWest life sciences cluster is home to leading life science companies such as AbbVie, Boston Scientific, Sanofi Genzyme and Sunovion. McCord acquired 30 Bearfoot from a subsidiary of Alexandria Real Estate Equities who owned the property for 15 years.
“Our approach to real estate is intentional. As we evaluate existing buildings for repositioning or land for new development, we look at how we can positively impact not only the asset, but the surrounding community,” said Ryan McCord, president at McCord. “Boston, just like Houston, is a hub of innovation. Now more than ever it is critical for us to deliver human-centric real estate experiences in these innovation hubs to promote further advancements within the medical and life science fields.”
For comments, questions or concerns, please contact David Cohen
- ◦Sale/Acquisition